{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T13:33:09Z","timestamp":1762608789546,"version":"build-2065373602"},"reference-count":64,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017547","name":"Spark Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017547","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.hoc.2022.03.009","type":"journal-article","created":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T07:28:57Z","timestamp":1656314937000},"page":"797-812","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Hemophilia A\/B"],"prefix":"10.1016","volume":"36","author":[{"given":"Stacy E.","family":"Croteau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.hoc.2022.03.009_bib1","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/ajh.26018","article-title":"2021 clinical trials update: Innovations in hemophilia therapy","volume":"96","author":"Croteau","year":"2021","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.hoc.2022.03.009_bib2","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/hae.13998","article-title":"Occurrence rates of haemophilia among males in the United States based on surveillance conducted in specialized haemophilia treatment centres","volume":"26","author":"Soucie","year":"2020","journal-title":"Haemophilia"},{"issue":"6","key":"10.1016\/j.hoc.2022.03.009_bib3","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.hoc.2022.03.009_bib4","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1365-2516.2011.02539.x","article-title":"Clinical severity of haemophilia A: does the classification of the 1950s still stand?","volume":"17","author":"Den Uijl","year":"2011","journal-title":"Haemophilia"},{"issue":"Suppl 6","key":"10.1016\/j.hoc.2022.03.009_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH Guidelines for the Management of Hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"issue":"24","key":"10.1016\/j.hoc.2022.03.009_bib6","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1182\/blood-2015-10-675140","article-title":"Men with severe hemophilia in the United States: birth cohort analysis of a large national database","volume":"127","author":"Mazepa","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2022.03.009_bib7","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3324\/haematol.2019.232132","article-title":"Hemophilia therapy: the future has begun","volume":"105","author":"Mannucci","year":"2020","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.hoc.2022.03.009_bib9","doi-asserted-by":"crossref","first-page":"e12601","DOI":"10.1002\/rth2.12601","article-title":"The impact of extended half-life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B","volume":"5","author":"Sun","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"11","key":"10.1016\/j.hoc.2022.03.009_bib10","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/bloodadvances.2019001311","article-title":"Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the Joint Outcome Continuation Study","volume":"4","author":"Warren","year":"2020","journal-title":"Blood Adv"},{"issue":"13","key":"10.1016\/j.hoc.2022.03.009_bib11","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1182\/blood-2014-08-535328","article-title":"FVIII inhibitors: pathogenesis and avoidance","volume":"125","author":"Astermark","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2022.03.009_bib12","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/bjh.12091","article-title":"Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization","volume":"160","author":"Collins","year":"2013","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.hoc.2022.03.009_bib13","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/hae.14357","article-title":"The B-Natural study-The outcome of immune tolerance induction therapy in patients with severe haemophilia B","volume":"27","author":"Astermark","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.hoc.2022.03.009_bib14","doi-asserted-by":"crossref","first-page":"670526","DOI":"10.3389\/fmed.2021.670526","article-title":"Progress in the development of anti-tissue factor pathway inhibitors for haemophilia management","volume":"8","author":"Mahlangu","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"23","key":"10.1016\/j.hoc.2022.03.009_bib15","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1056\/NEJM200106073442301","article-title":"Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A","volume":"344","author":"Roth","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.hoc.2022.03.009_bib16","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1182\/blood-2011-09-382317","article-title":"Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer","volume":"119","author":"Buchlis","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2022.03.009_bib17","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood-2003-01-0167","article-title":"Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion","volume":"102","author":"Powell","year":"2003","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2022.03.009_bib18","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat Med"},{"issue":"25","key":"10.1016\/j.hoc.2022.03.009_bib19","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.hoc.2022.03.009_bib20","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2022.03.009_bib21","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1182\/blood-2018-99-118334","article-title":"Adeno-associated mediated gene transfer for hemophilia b:8 year follow up and impact of removing \"empty viral particles\" on safety and efficacy of gene transfer","volume":"132","author":"Nathwani","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2022.03.009_bib22","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ymthe.2006.05.009","article-title":"Adeno-associated virus serotypes: vector toolkit for human gene therapy","volume":"14","author":"Wu","year":"2006","journal-title":"Mol Ther"},{"key":"10.1016\/j.hoc.2022.03.009_bib23","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.omtm.2019.05.014","article-title":"Prevalence of anti-adeno-associated virus immune responses in international cohorts of healthy donors","volume":"14","author":"Kruzik","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"12","key":"10.1016\/j.hoc.2022.03.009_bib24","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1182\/blood-2010-08-302729","article-title":"Assessing the potential for AAV vector genotoxicity in a murine model","volume":"117","author":"Li","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2022.03.009_bib25","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","article-title":"Immune responses to AAV vectors: overcoming barriers to successful gene therapy","volume":"122","author":"Mingozzi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2022.03.009_bib26","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1182\/asheducation.V2012.1.375.3797885","article-title":"The gene therapy journey for hemophilia: are we there yet?","volume":"2012","author":"High","year":"2012","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.hoc.2022.03.009_bib27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.omtm.2019.05.009","article-title":"Therapeutic hFIX Activity Achieved after Single AAV5-hFIX Treatment in Hemophilia B Patients and NHPs with Pre-existing Anti-AAV5 NABs","volume":"14","author":"Majowicz","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.hoc.2022.03.009_bib28","doi-asserted-by":"crossref","first-page":"100759","DOI":"10.1016\/j.blre.2020.100759","article-title":"Discussing investigational AAV gene therapy with hemophilia patients: A guide","volume":"47","author":"Sidonio","year":"2021","journal-title":"Blood Rev"},{"issue":"6","key":"10.1016\/j.hoc.2022.03.009_bib29","first-page":"357","article-title":"Adeno-associated virus vectors for gene therapy","volume":"2","author":"Flotte","year":"1995","journal-title":"Gene Ther"},{"issue":"2 Suppl 4","key":"10.1016\/j.hoc.2022.03.009_bib30","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0037-1963(01)90103-9","article-title":"Structural and functional characterization of B-domain deleted recombinant factor VIII","volume":"38","author":"Sandberg","year":"2001","journal-title":"Semin Hematol"},{"issue":"17","key":"10.1016\/j.hoc.2022.03.009_bib31","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1182\/blood-2012-10-462200","article-title":"Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant","volume":"121","author":"McIntosh","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2022.03.009_bib32","first-page":"1","article-title":"Hemophilia A gene therapy: current and next-generation approaches","volume":"6","author":"Pipe","year":"2022","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"10.1016\/j.hoc.2022.03.009_bib33","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/hum.2014.106","article-title":"Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial","volume":"26","author":"Monahan","year":"2015","journal-title":"Hum Gene Ther"},{"issue":"17","key":"10.1016\/j.hoc.2022.03.009_bib34","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa0904377","article-title":"X-linked thrombophilia with a mutant factor IX (factor IX Padua)","volume":"361","author":"Simioni","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.hoc.2022.03.009_bib35","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1182\/blood.2020006005","article-title":"Gene therapy for hemophilia B using CB 2679d-GT: a novel factor IX variant with higher potency than factor IX Padua","volume":"137","author":"Nair","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2022.03.009_bib36","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1182\/blood-2010-05-282707","article-title":"Codon optimization of human factor VIII cDNAs leads to high-level expression","volume":"117","author":"Ward","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2022.03.009_bib37","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1172\/JCI68205","article-title":"CpG-depleted adeno-associated virus vectors evade immune detection","volume":"123","author":"Faust","year":"2013","journal-title":"J\u00a0Clin Invest"},{"issue":"6","key":"10.1016\/j.hoc.2022.03.009_bib38","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood.2019004625","article-title":"BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression","volume":"137","author":"Konkle","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2022.03.009_bib39","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa1908490","article-title":"Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A","volume":"382","author":"Pasi","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.hoc.2022.03.009_bib40","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2104205","article-title":"Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A","volume":"385","author":"George","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.hoc.2022.03.009_bib41","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2017-09-804419","article-title":"Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B","volume":"131","author":"Miesbach","year":"2018","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.hoc.2022.03.009_bib42","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B gene therapy with a high-specific-activity factor IX variant","volume":"377","author":"George","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.hoc.2022.03.009_bib43","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5-Factor VIII Gene Transfer in Severe Hemophilia A","volume":"377","author":"Rangarajan","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.hoc.2022.03.009_bib44","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/bloodadvances.2019000811","article-title":"Etranacogene dezaparvovec (AMT-061 phase 2b): normal\/near normal FIX activity and bleed cessation in hemophilia B","volume":"3","author":"Von Drygalski","year":"2019","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.hoc.2022.03.009_bib45","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.ymthe.2017.02.014","article-title":"The Balance between CD8(+) T Cell-Mediated Clearance of AAV-Encoded Antigen in the Liver and Tolerance Is Dependent on the Vector Dose","volume":"25","author":"Kumar","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.hoc.2022.03.009_bib46","doi-asserted-by":"crossref","first-page":"16063","DOI":"10.1038\/mtm.2016.63","article-title":"Potential for cellular stress response to hepatic factor VIII expression from AAV vector","volume":"3","author":"Zolotukhin","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"Suppl 6","key":"10.1016\/j.hoc.2022.03.009_bib47","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/hae.13489","article-title":"Past, present and future of haemophilia gene therapy: From vectors and transgenes to known and unknown outcomes","volume":"24","author":"Pierce","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.hoc.2022.03.009_bib48","unstructured":"MASAC Recommendation for Liver Biopsies in Gene Therapy Trials for Hemophilia [press release]. 2019. Available at: https:\/\/www.hemophilia.org\/healthcare-professionals\/guidelines-on-care\/masac-documents\/masac-document-256-recommendation-for-liver-biopsies-in-gene-therapy-trials-for-hemophilia#:\u223c:text=Takeda%20Shoes-,MASAC%20Document%20256%20%2D%20Recommendation%20for%20Liver%20Biopsies,Gene%20Therapy%20Trials%20for%20Hemophilia&text=Currently%2C%20adeno%2Dassociated%20virus%20(,a%20variety%20of%20monogenic%20diseases."},{"issue":"9","key":"10.1016\/j.hoc.2022.03.009_bib49","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/mt.2009.150","article-title":"Strategies to modulate immune responses: a new frontier for gene therapy","volume":"17","author":"Arruda","year":"2009","journal-title":"Mol Ther"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2022.03.009_bib50","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2020-139225","article-title":"AMT-060 Gene Therapy in Adults with Severe or Moderate-Severe Hemophilia B Confirm Stable FIX Expression and Durable Reductions in Bleeding and Factor IX Consumption for up to 5 Years","volume":"136","author":"Leebeek","year":"2020","journal-title":"Blood"},{"issue":"Suppl 2","key":"10.1016\/j.hoc.2022.03.009_bib51","article-title":"Etranacogene Dezaparvovec (AAV5-Padua hFIX Variant, AMT-061), an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-severe Hemophilia B: 2.5 Year Data from a Phase 2b\u00a0Trial [abstract]","volume":"5","author":"Gomez","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"Suppl 2","key":"10.1016\/j.hoc.2022.03.009_bib52","article-title":"52 Week Efficacy and Safety of Etranacogene Dezaparvovec in Adults with Severe or Moderate-severe Hemophilia B: Data from the Phase 3 HOPE-B Gene Therapy Trial [abstract]","volume":"5","author":"Pipe","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"Supplement_1","key":"10.1016\/j.hoc.2022.03.009_bib53","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1182\/blood-2019-124091","article-title":"Efficacy and Safety in 15 Hemophilia B Patients Treated with the AAV Gene Therapy Vector Fidanacogene Elaparvovec and Followed for at Least 1 Year","volume":"134","author":"George","year":"2019","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2022.03.009_bib54","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood-2020-139803","article-title":"First-in-human gene therapy study of AAVhu37 capsid vector technology in severe hemophilia A - BAY 2599023 has broad patient eligibility and stable and sustained long-term expression of FVIII","volume":"136","author":"Pipe","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2022.03.009_bib55","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","article-title":"Emerging issues in AAV-mediated in\u00a0vivo gene therapy","volume":"8","author":"Colella","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.hoc.2022.03.009_bib57","doi-asserted-by":"crossref","first-page":"15056","DOI":"10.1038\/mtm.2015.56","article-title":"Effects of FVIII immunity on hepatocyte and hematopoietic stem cell-directed gene therapy of murine hemophilia A","volume":"3","author":"Lytle","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.hoc.2022.03.009_bib58","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.omtm.2018.01.011","article-title":"Platelet-targeted gene therapy for hemophilia","volume":"9","author":"Shi","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"6","key":"10.1016\/j.hoc.2022.03.009_bib59","doi-asserted-by":"crossref","first-page":"101397","DOI":"10.1016\/j.jbc.2021.101397","article-title":"Transduction of modified Factor VIII gene improves lentiviral gene therapy efficacy for hemophilia A","volume":"297","author":"Gong","year":"2021","journal-title":"J\u00a0Biol Chem"},{"issue":"10","key":"10.1016\/j.hoc.2022.03.009_bib60","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1089\/hum.2018.137","article-title":"Preclinical development of a hematopoietic stem and progenitor cell bioengineered factor VIII lentiviral Vector gene therapy for hemophilia A","volume":"29","author":"Doering","year":"2018","journal-title":"Hum Gene Ther"},{"issue":"S3","key":"10.1016\/j.hoc.2022.03.009_bib61","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/hae.14056","article-title":"WFH State-of-the-art paper 2020: In\u00a0vivo lentiviral vector gene therapy for haemophilia","volume":"27","author":"Cantore","year":"2021","journal-title":"Haemophilia"},{"issue":"13","key":"10.1016\/j.hoc.2022.03.009_bib62","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1056\/NEJMcibr1600347","article-title":"Genetic targeting of the albumin locus to treat hemophilia","volume":"374","author":"Davidoff","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.hoc.2022.03.009_bib63","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s00439-016-1699-x","article-title":"Genome-editing technologies for gene correction of hemophilia","volume":"135","author":"Park","year":"2016","journal-title":"Hum Genet"},{"key":"10.1016\/j.hoc.2022.03.009_bib64","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.omtm.2020.06.025","article-title":"CRISPR-Cas9-mediated in\u00a0vivo gene integration at the albumin locus recovers hemostasis in neonatal and adult hemophilia B mice","volume":"18","author":"Wang","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.hoc.2022.03.009_bib65","first-page":"897","article-title":"Integrated hemophilia patient care via a national network of care centers in the United States: a model for rare coagulation disorders","volume":"12","author":"Valentino","year":"2021","journal-title":"J\u00a0Blood Med"},{"issue":"4","key":"10.1016\/j.hoc.2022.03.009_bib66","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.1111\/hae.13504","article-title":"Core outcome set for gene therapy in haemophilia: Results of the coreHEM multistakeholder project","volume":"24","author":"Iorio","year":"2018","journal-title":"Haemophilia"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858822000302?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858822000302?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:18:08Z","timestamp":1760185088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858822000302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":64,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S0889858822000302"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2022.03.009","relation":{},"ISSN":["0889-8588"],"issn-type":[{"type":"print","value":"0889-8588"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hemophilia A\/B","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2022.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}